Form 4: Calidi Biotherapeutics Director Alan R. Stewart Acquires 73,437 Shares of Common Stock

Director Alan R. Stewart acquired 73,437 shares of Calidi Biotherapeutics common stock on June 28, 2024, increasing his holdings to 154,087 shares.

Summary

• On June 28, 2024, Alan R. Stewart, a director of Calidi Biotherapeutics, Inc., acquired 73,437 shares of common stock.
• The acquisition was in the form of restricted stock units (RSUs) granted under the Issuer's 2023 Equity Incentive Plan.
• The RSUs fully vested on the grant date.
• Following the transaction, Stewart's total beneficial ownership of Calidi Biotherapeutics common stock increased to 154,087 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock acquisition by a director, which can be interpreted as a positive sign of confidence, but it doesn't provide substantial information about the company's performance or future prospects.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Key Dates